StockData
Lakewood-Amedex Biotherapeutics Inc. logo

Lakewood-Amedex Biotherapeutics Inc. (LABT) income statement

LABTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$0.24+0.03 (+11.89%)

Close on Nov 18, 2026Market cap $568.73KP/E –Yield –

Lakewood-Amedex Biotherapeutics Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
–

Financial strength

Current ratio
5.22
Debt to equity
–
Debt to assets
–
Cash to current liabilities
419.4%

Valuation

P/E ratio
–
Price to sales
–
Price to book
0.19
Dividend yield
–

See a number that looks wrong?